Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 20.24 USD -2.41% Market Closed
Market Cap: $1B

Net Margin

36.5%
Current
Declining
by 350.9%
vs 3-y average of 387.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
36.5%
=
Net Income
$29.3m
/
Revenue
$80.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
36.5%
=
Net Income
$29.3m
/
Revenue
$80.3m

Peer Comparison

Country Company Market Cap Net
Margin
KY
Theravance Biopharma Inc
NASDAQ:TBPH
1B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...

Market Distribution

Higher than 100% of companies in Cayman Islands
Percentile
100th
Based on 101 companies
100th percentile
36.5%
Low
-9 935.2% — -5.8%
Typical Range
-5.8% — 6.5%
High
6.5% — 36.5%
Distribution Statistics
Cayman Islands
Min -9 935.2%
30th Percentile -5.8%
Median -0.3%
70th Percentile 6.5%
Max 36.5%

Theravance Biopharma Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

TBPH Intrinsic Value
12.36 USD
Overvaluation 39%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
36.5%
=
Net Income
$29.3m
/
Revenue
$80.3m
What is Theravance Biopharma Inc's current Net Margin?

The current Net Margin for Theravance Biopharma Inc is 36.5%, which is below its 3-year median of 387.4%.

How has Net Margin changed over time?

Over the last 3 years, Theravance Biopharma Inc’s Net Margin has decreased from 1 645.1% to 36.5%. During this period, it reached a low of -105% on Sep 30, 2023 and a high of 1 802.3% on Mar 31, 2023.

Back to Top